Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thrombomodulin siRNA is a small interfering RNA designed to silence the expression of the thrombomodulin (TM) gene. Thrombomodulin is a cell surface glycoprotein typically found on endothelial cells, where it acts as a vascular protective molecule with anticoagulant and anti-inflammatory properties. However, research has indicated that TM is upregulated in certain malignancies, such as bladder cancer, where it may promote tumor progression, proliferation, and invasion. By utilizing siRNA to knock down TM expression, researchers aim to inhibit these oncogenic processes. In preclinical models of bladder cancer, TM siRNA has demonstrated the ability to reduce cancer cell proliferation, migration, and colony formation, suggesting its potential as a therapeutic strategy for invasive urothelial carcinomas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thrombomodulin siRNA.